Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults
Description
CONCLUSIONS: NVX-CoV2373 showed consistent immunogenicity between lots, with no new safety signals identified. Use of NVX-CoV2373 as a booster dose (first or later) is supported.
